---
title: "References"
description: "Complete numbered reference list for the psoriasis book, including primary research articles, reviews, guidelines, and registry data."
sidebar:
  order: 26
---

1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *JAMA*. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32427307/)

2. Sieminska I, Pieniawska M, Grzywa TM. The immunology of psoriasis — current concepts in pathogenesis. *Clin Rev Allergy Immunol*. 2024;66(2):164-191. doi:10.1007/s12016-024-08991-7. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11193704/)

3. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. *Lancet*. 2021;397(10281):1301-1315. doi:10.1016/S0140-6736(20)32549-6. [Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32549-6/abstract)

4. Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. *J Allergy Clin Immunol*. 2017;140(3):645-653. doi:10.1016/j.jaci.2017.07.004. [Full text](https://www.jacionline.org/article/S0091-6749(17)31197-1/fulltext)

5. Dand N, Mahil SK, Capon F, et al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. *Nat Commun*. 2025;16:2051. doi:10.1038/s41467-025-56719-8. [Nature](https://www.nature.com/articles/s41467-025-56719-8)

6. Capon F. Psoriasis and genetics. *Acta Derm Venereol*. 2020;100(3):adv00030. [Full text](https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3384)

7. Gelfand JM et al. A partitioned 88-loci psoriasis genetic risk score reveals HLA and non-HLA contributions to clinical phenotypes in a Newfoundland psoriasis cohort. *Front Genet*. 2023;14:1141010. [Frontiers](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1141010/full)

8. Strange A, Capon F, Spencer CCA, et al. Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet*. 2010;42(11):985-990. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3749730/)

9. El-Boghdady NA et al. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. *Cureus*. 2023;15(7):e42415. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10418823/)

10. Li M, et al. Genetics of psoriasis: a basis for precision medicine. *Precis Clin Med*. 2019;2(2):120-130. doi:10.1093/pcmedi/pbz010. [Oxford Academic](https://academic.oup.com/pcm/article/2/2/120/5522496)

11. Xiong Y, Xue J, Tong M, Xu T, Bai X. Dynamic trend analysis of global psoriasis burden from 1990 to 2021. *Front Public Health*. 2025;13:1518681. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12283580/)

12. Dimmock PW, Aalemi AK, Parisi R, et al. Global epidemiology of psoriasis: Global Psoriasis Atlas 2024 update. *Br J Dermatol*. 2024;191(Suppl_3):ljae360.061. [Oxford Academic](https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.061/7916197)

13. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. *J Eur Acad Dermatol Venereol*. 2017;31(2):205-212. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27573025/)

14. Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol*. 2013;133(2):377-385. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23014338/)

15. Dairov A, Issabekova A, Sekenova A, et al. Prevalence, incidence, gender and age distribution, and economic burden of psoriasis worldwide and in Kazakhstan. *J Clin Med Kazakhstan*. 2024;21(2):18-30. [Full text (PDF)](https://www.clinmedkaz.org/download/prevalence-incidence-gender-and-age-distribution-and-economic-burden-of-psoriasis-worldwide-and-in-14497.pdf)

16. Zhu X, Zheng A, et al. Triggers for the onset and recurrence of psoriasis: a review and update. *Cell Commun Signal*. 2024;22:108. doi:10.1186/s12964-023-01381-0. [Springer](https://link.springer.com/article/10.1186/s12964-023-01381-0)

17. Ko SH, et al. Lifestyle changes for treating psoriasis. *Cochrane Database Syst Rev*. 2019;7:CD011972. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6629583/)

18. Naldi L. Psoriasis and smoking: links and risks. *Psoriasis (Auckl)*. 2016;6:65-71. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5683129/)

19. Luca M, et al. The role of smoking in psoriasis. *Medicina (Kaunas)*. 2024;60(5):856. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11110215/)

20. Zhou W, et al. Tobacco smoking negatively influences the achievement of greater than three-quarters reduction in PASI after eight weeks of treatment. *Tob Induc Dis*. 2024;22:60. [Full text](https://www.tobaccoinduceddiseases.org/Tobacco-smoking-negatively-influences-the-achievement-of-greater-than-three-quarters,184143,0,2.html)

21. Caso F, et al. The role of lifestyle and nutrition in psoriasis: current status of knowledge and interventions. *Dermatol Ther*. 2022;35(11):e15811. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC9541512/)

22. Takahashi H, Iizuka H. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. *Intern Med*. 2012;51(18):2471-2477. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5519460/)

23. Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. *Int J Mol Sci*. 2017;18(10):2211. [MDPI](https://www.mdpi.com/1422-0067/18/10/2211)

24. Ni C, Chiu MW. Psoriasis and comorbidities: links and risks. *Clin Cosmet Investig Dermatol*. 2014;7:119-132. [Dove Press](https://www.dovepress.com/psoriasis-and-comorbidities-links-and-risks-peer-reviewed-fulltext-article-CCID)

25. Mehta NN, et al. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. *J Am Coll Cardiol*. 2021;77(13):1670-1680. [JACC](https://www.jacc.org/doi/10.1016/j.jacc.2021.02.009)

26. National Psoriasis Foundation. What are the related medical conditions of psoriasis? Updated 2024. [Website](https://www.psoriasis.org/related-conditions/)

27. ten Bergen LL, et al. The TNF/IL-23/IL-17 axis — head-to-head trials comparing different biologics in psoriasis treatment. *Scand J Immunol*. 2020;92(4):e12946. [Wiley](https://onlinelibrary.wiley.com/doi/10.1111/sji.12946)

28. Fatani M, et al. Review on recommendations on the use of biologic treatments for psoriasis. *Expert Opin Biol Ther*. 2025. [Taylor & Francis (PDF)](https://www.tandfonline.com/doi/pdf/10.1080/14712598.2025.2495986)

29. Comparative efficacy of TNF-alpha inhibitors, IL-17 and IL-23 inhibitors. *IJFMR*. 2024;6(6):29806. [Full text (PDF)](https://www.ijfmr.com/papers/2024/6/29806.pdf)

30. Balogh EA, et al. From the Masterclasses in Dermatology 2024: Updates in psoriasis treatments. *Dermatol Ther (Heidelb)*. 2025;15:539-554. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11896623/)

31. Dey AK, et al. Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents. *Pharmaceuticals (Basel)*. 2024;17(1):137. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819460/)

32. Gopika M, et al. Advances in psoriasis research: from pathogenesis to therapeutics. *Life Sci*. 2024;355:122935. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0024320524005812)

33. Al-Kufi SNH, et al. Advancements in understanding and treating psoriasis: a comprehensive review. *PeerJ*. 2025;13:e19354. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12047224/)

34. Tsankov NK, et al. Advances in understanding the immunological pathways in psoriasis. *Int J Mol Sci*. 2019;20(3):739. [MDPI](https://www.mdpi.com/1422-0067/20/3/739)

35. Armstrong AW, et al. Psoriasis. *Nat Rev Dis Primers*. 2025;11:46. [Nature](https://www.nature.com/articles/s41572-025-00630-5)

36. Wang X, et al. Global burden of psoriasis from 1990 to 2021 and potential factors: a systematic analysis. *J Invest Dermatol*. 2025 (in press). [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S0022202X25024157)

37. Li X, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. *Int Immunopharmacol*. 2019;62:46-58. [ScienceDirect](https://www.sciencedirect.com/science/article/abs/pii/S1567576918302716)

38. Fotiadou C, et al. New therapies in the biological treatment of psoriasis: a review. *Biologics*. 2025;5(2):19. [MDPI](https://www.mdpi.com/2313-5786/5/2/19)

39. Liu J, et al. Critical role of environmental factors in the pathogenesis of psoriasis. *J Dermatol*. 2017;44(8):863-872. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28349593/)

40. Xie X, et al. Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. *Dermatol Ther (Heidelb)*. 2025;15:1497-1527. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC12126413/)

41. Chen H, et al. Systemic psoriasis: from molecular mechanisms to global management strategies. *Clin Rev Allergy Immunol*. 2025. doi:10.1007/s12016-025-09089-4. [Springer](https://link.springer.com/article/10.1007/s12016-025-09089-4)

42. Johnson M. What we know about psoriasis comorbidities and their management. *Dermatology Education Foundation*. 2024. [Website](https://dermnppa.org/what-we-know-about-psoriasis-comorbidities-and-their-management/)

43. Li T, et al. A practical guide to biologic treatments for psoriasis in Asia. *Asian Pac J Allergy Immunol*. 2025 (online). [Full text (PDF)](https://apjai-journal.org/wp-content/uploads/2025/10/7_AP-240425-2072.pdf)

44. Cheng Y, et al. GWAS and comprehensive analysis of psoriasis in the Taiwanese population. *Mol Med Rep*. 2024;30(1):104. [Spandidos](https://www.spandidos-publications.com/10.3892/mmr.2024.13239)

45. Egilman AC, Kesselheim AS, Avorn J, Raymakers AJN, Rome BN. Use of efficiency frontiers to align prices and clinical benefits of biologic therapies for plaque psoriasis. *JAMA Dermatol*. 2024;160(4):409-416. doi:10.1001/jamadermatol.2023.6236. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC10882509/)

46. Rome BN, Han J, Mooney H, Kesselheim AS. Use and cost of first-line biologic medications to treat plaque psoriasis in the US. *JAMA Dermatol*. 2025;161(6):622-628. doi:10.1001/jamadermatol.2025.0669. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40238112/)

47. National Psoriasis Foundation. Biosimilars for psoriasis and psoriatic arthritis. Updated March 24, 2025. [Website](https://www.psoriasis.org/biosimilars/)

48. National Psoriasis Foundation. Current biologics on the market for psoriatic disease. [Website](https://www.psoriasis.org/current-biologics-on-the-market/)

49. Segal. Specialty dermatological drug cost trends Q3 2025. [Website](https://www.segalco.com/consulting-insights/q3-2025-trends-focus-specialty-dermatological-drugs)

50. Dermatology Advisor. Biosimilars for psoriasis treatment. November 5, 2025. [Website](https://www.dermatologyadvisor.com/features/biosimilars-for-psoriasis/)

51. Lewitt G, et al. Psoriasis therapies in 2024 and beyond. *Dermatology Times*. 2024. [Website](https://www.dermatologytimes.com/view/psoriasis-therapies-in-2024-and-beyond)

52. Brajac I, Gruber F. History of Psoriasis. In: O'Daly J, editor. *Psoriasis — A Systemic Disease*. Rijeka: IntechOpen; 2012. p. 57-68. doi:10.5772/27640. [IntechOpen](https://doi.org/10.5772/27640)

53. Holubar K. Psoriasis and parapsoriasis: since 200 and 100 years, respectively. *J Eur Acad Dermatol Venereol*. 2003;17(2):126-127. doi:10.1046/j.1468-3083.2003.00622.x. [JEADV](https://doi.org/10.1046/j.1468-3083.2003.00622.x)

54. Willan R. *On Cutaneous Diseases*. Vol. 1. London: J. Johnson; 1808. [Internet Archive](https://archive.org/details/2577014R.nlm.nih.gov)

55. Auspitz H. Ueber das Verhaltniss der Oberhaut zur Papillarschicht. *Archiv fur Dermatologie und Syphilis*. 1870;2:24-58. doi:10.1007/BF01822714. [Springer](https://doi.org/10.1007/BF01822714)

56. Ingram JT. The approach to psoriasis. *Br Med J*. 1953;2(4836):591-594. doi:10.1136/bmj.2.4836.591. [BMJ](https://doi.org/10.1136/bmj.2.4836.591)

57. Dennis M, Bhutani T, Koo J, Liao W. The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis. *J Dermatolog Treat*. 2013;24(4):319-327. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3735239/)

58. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. *AMA Arch Derm*. 1958;78:200-203. [PubMed](https://pubmed.ncbi.nlm.nih.gov/13571257/)

59. Mueller W, Herrmann B. Cyclosporin A for psoriasis. *N Engl J Med*. 1979;301:555. [PubMed](https://pubmed.ncbi.nlm.nih.gov/460325/)

60. Eedy DJ, Burrows D, Bridges JM, Jones FG. Clearance of severe psoriasis after allogenic bone marrow transplantation. *BMJ*. 1990;300(6729):908. doi:10.1136/bmj.300.6729.908. [BMJ](https://doi.org/10.1136/bmj.300.6729.908)

61. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol*. 2010;146(8):891-895. doi:10.1001/archdermatol.2010.186. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20713823/)

62. Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. *J Invest Dermatol*. 2015;135(4):984-991. doi:10.1038/jid.2014.530. [PubMed](https://pubmed.ncbi.nlm.nih.gov/25521458/)

63. Williams K, Lada G, Reynolds NJ, et al. Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from BADBIR. *Clin Exp Dermatol*. 2025;50(4):804-811. doi:10.1093/ced/llae449. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39425683/)

64. Griffiths CEM, Fava M, Miller AH, et al. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis. *Psychother Psychosom*. 2017;86(5):260-267. doi:10.1159/000479163. [PubMed](https://pubmed.ncbi.nlm.nih.gov/28903122/)

65. Abboud E, Chrayteh D, Boussetta N, et al. Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment. *Nat Commun*. 2024;15(1):6718. doi:10.1038/s41467-024-50993-8. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC11306357/)

66. Olafsson S, Rodriguez E, Lawson ARJ, et al. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of the skin. *Nat Genet*. 2023;55(11):1892-1900. doi:10.1038/s41588-023-01545-1. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37884686/)

67. Bissonnette R, Soung J, Hebert AA, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. *N Engl J Med*. 2025;393(18):1784-1795. doi:10.1056/NEJMoa2504187. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41191940/)

68. Tehlirian C, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. *JAMA Dermatol*. 2024. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39167366/)

69. Nielsen ML, Thein D, Rasmussen MK, et al. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study. *J Am Acad Dermatol*. 2023;88(6):1378-1381. doi:10.1016/j.jaad.2023.01.029. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36739903/)

70. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. *Arch Dermatol*. 2005;141(5):601-606. doi:10.1001/archderm.141.5.601. [PubMed](https://pubmed.ncbi.nlm.nih.gov/15793512/)

71. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis*. 2018;77(2):228-233. doi:10.1136/annrheumdis-2017-212196. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29030361/)

72. Jeong YD, Jo H, Cho H, et al. Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes: Findings from WHO Pharmacovigilance Study. *Int Arch Allergy Immunol*. 2025;186(6):579-593. doi:10.1159/000542217. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39626647/)

73. National Institute for Health and Care Excellence. Psoriasis: assessment and management (CG153). Updated September 2017. [NICE](https://www.nice.org.uk/guidance/cg153)

74. Meeuwis KAP, de Hullu JA, van de Nieuwenhof HP, Evers AWM, Massuger LFAG, van de Kerkhof PCM, van Rossum MM. Quality of life and sexual health in patients with genital psoriasis. *Br J Dermatol*. 2011;164(6):1247-1255. doi:10.1111/j.1365-2133.2011.10249.x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21569104/)

75. Mahil SK, Dand N, Mason KJ, et al.; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis — insights from a global registry-based study. *J Allergy Clin Immunol*. 2021;147(1):60-71. doi:10.1016/j.jaci.2020.10.007. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33075408/)

76. Yiu ZZN, Ashcroft DM, Evans I, et al.; BADBIR Study Group. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from BADBIR. *Br J Dermatol*. 2019;180(2):329-337. doi:10.1111/bjd.17036. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30070708/)

77. MacKenna B, Kennedy NA, Mehrkar A, et al. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. *Lancet Rheumatol*. 2022;4(7):e490-e506. doi:10.1016/S2665-9913(22)00098-4. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35698725/)

78. Mahil SK, Bechman K, Raharja A, et al. Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study. *Lancet Rheumatol*. 2022;4(1):e42-e52. doi:10.1016/S2665-9913(21)00333-7. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34778846/)

79. Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. *Ann Rheum Dis*. 2021;80(10):1339-1344. doi:10.1136/annrheumdis-2021-220597. [PubMed](https://pubmed.ncbi.nlm.nih.gov/34035003/)

80. Haberman RH, Um S, Engel AJ, et al.; SAGA investigators. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. *Lancet Rheumatol*. 2022;4(6):e384-e387. doi:10.1016/S2665-9913(22)00069-8. [PubMed](https://pubmed.ncbi.nlm.nih.gov/35403000/)

81. Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2 — Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. *J Am Acad Dermatol*. 2021;84(5):1254-1268. doi:10.1016/j.jaad.2020.12.058. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33422626/)

82. Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, et al. Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. *JAMA Dermatol*. 2025;161(12):1215-1223. doi:10.1001/jamadermatol.2025.3410. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40991259/)

83. Bittiner SB, Tucker WF, Cartwright I, Bleehen SS. A double-blind, randomised, placebo-controlled trial of fish oil in psoriasis. *Lancet*. 1988;1(8582):378-380. doi:10.1016/S0140-6736(88)91181-6. [PubMed](https://pubmed.ncbi.nlm.nih.gov/2893189/)

84. Soyland E, Funk J, Rajka G, et al. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. *N Engl J Med*. 1993;328(25):1812-1816. doi:10.1056/NEJM199306243282504. [PubMed](https://pubmed.ncbi.nlm.nih.gov/8502270/)

85. Huang YW, Tsai TF. Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience. *Dermatol Ther (Heidelb)*. 2019;9(3):553-569. doi:10.1007/s13555-019-0310-5. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31270683/)

86. Armstrong AW, Gondo GC, Merola JF, et al.; Remission Workgroup of the National Psoriasis Foundation. Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation. *JAMA Dermatol*. 2025;161(8):863-869. doi:10.1001/jamadermatol.2025.1625. [PubMed](https://pubmed.ncbi.nlm.nih.gov/40531503/)

87. Ibrahim GH, Buch MH, Lawson C, Rajber R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. *Clin Exp Rheumatol*. 2009;27(3):469-474. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19174392/)

88. Chen H, Poon A, Yeung C, et al. A Genetic Risk Score Combining Ten Psoriasis Risk Loci Improves Disease Prediction. *PLoS ONE*. 2011;6(4):e19454. doi:10.1371/journal.pone.0019454. [PLOS ONE](https://doi.org/10.1371/journal.pone.0019454)

89. Kolchak NA, Tetarnikova MK, Theodoropoulou MS, Michalopoulou AP, Theodoropoulos DS. Prevalence of antigliadin IgA antibodies in psoriasis vulgaris and response of seropositive patients to a gluten-free diet. *J Multidiscip Healthc*. 2018;11:13-19. doi:10.2147/JMDH.S122256. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29343966/)

90. Jensen P, Zachariae C, Christensen R, et al. Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study. *Am J Clin Nutr*. 2016;104(2):259-265. doi:10.3945/ajcn.115.125849. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27334236/)

91. Mackensen A, Muller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nat Med*. 2022;28(10):2124-2132. doi:10.1038/s41591-022-02017-5. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36109639/)

92. Muller F, Boeltz S, Knitza J, Schett G, et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. *N Engl J Med*. 2024;390(8):687-700. doi:10.1056/NEJMoa2308917. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38381673/)

93. Wang SY, An WH, Wang ZS, et al. Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report. *Front Immunol*. 2024;15:1418768. doi:10.3389/fimmu.2024.1418768. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39534606/)

94. Yi JZ, McGee JS. Epigenetic-modifying therapies: an emerging avenue for the treatment of inflammatory skin diseases. *Exp Dermatol*. 2021;30(8):1167-1176. doi:10.1111/exd.14334. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33752257/)

95. Nadeem A, Al-Harbi NO, Al-Harbi MM, et al. Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation. *Pharmacol Res*. 2015;99:248-257. doi:10.1016/j.phrs.2015.06.001. [PubMed](https://pubmed.ncbi.nlm.nih.gov/26149470/)

96. Huang K, Wu X, Li Y, et al. Artificial intelligence-based psoriasis severity assessment: real-world study and application. *J Med Internet Res*. 2023;25:e44932. doi:10.2196/44932. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36927843/)

97. Goessinger EV, Gottfrois P, Mueller AM, Cerminara SE, Navarini AA. Image-based artificial intelligence in psoriasis assessment: the beginning of a new diagnostic era? *Am J Clin Dermatol*. 2024;25(6):861-872. doi:10.1007/s40257-024-00883-y. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39259262/)

98. Zhang X, He Y. The role of nociceptive neurons in the pathogenesis of psoriasis. *Front Immunol*. 2020;11:1984. doi:10.3389/fimmu.2020.01984. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33133059/)

99. Sayed BA, et al. Apremilast: First Pediatric Approval. *Paediatr Drugs*. 2024. doi:10.1007/s40272-024-00659-x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39576565/)

100. Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. In: Weinberg JM, Lebwohl M, editors. *Advances in Psoriasis*. Springer; 2021. p. 1-16. [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC7122924/)
